Medicines Transparency Alliance13/09/2015 1 MeTA Jordan Country Overview Public Sector Private...

Medicines Transparency Alliance21/04/23 1

MeTA Jordan

Country OverviewPublic SectorPrivate SectorCivil Society


MeTA Jordan

Dr Taher Abu ElSamenMeTA Council ChairHHC Secretary General


Multi-stakeholder process (1)

The Multi-stakeholder process in Jordan started by:

Establishing the MeTA Council based on a multi-stakeholder membership , the MeTA Council is represented fully by multi-stakeholder, public and private sectors and the CSO, and they all agreed on a national country workplan

Medicines Transparency Alliance

Multi-stakeholder in MeTA Council

WHO DFID WB04/21/23

MeTA Int. Partners



MeTA Jordan used the national forum Nov. 2009 as an opportunity to re-motivate and engage stakeholders especially the private sector and the CSOs. The diversity of the represented attendees gave a unique flavor for the forum especially during the discussion session

The one day multi-stakeholder collaboration for MeTA pilot countries workshop carried out by Wageningen University in January 2010 was a success, 70 attendees from all MeTA Countries attended, since it supported the multi-stakeholder dialogue and collaboration by encouraging the active participation of key stakeholders from public, private and CSOs

Conducting the data disclosure survey was an opportunity not only to collect data but also to work together as a multi-stakeholder, share information and exchange ideas which created more interest and commitment for future activities

21/04/23 5



MeTA Jordan will carry out the stakeholder mapping and communication audits in July 2010 through the IDS (part of Component 3 of the MeTA baseline assessment) to help map out the local communication partners and individual consultants. The work aims to create ‘communication’ or ‘learning’ spaces where MeTA representatives have a chance to reflect on their experiences and share these with a view to encouraging innovation and change

Having MeTA in Jordan was an opportunity to get key people working in the pharmaceutical sector engage together in a multi-stakeholder membership and including patients along the way

MeTA Jordan stakeholders reached a stage that they need skills to help them communicate with representatives of institutional partners who may come from very different positions

21/04/23 6



MeTA Jordan stakeholders are thinking strategically to develop a clear brand identity for MeTA and to recommend development of communication tools and messages to support the multi-stakeholder process

The International MeTA Secretariat offered countries to identify and communicate the barriers and ensure that the appropriate guidance and support is mobilised within MeTA to address them

21/04/23 7


Multi-stakeholder Milestones

Establishing a multi-stakeholder MeTA Council

MeTA Jordan national forum invited multi-stakeholder Nov. 2009

One day multi-stakeholder collaboration for MeTA pilot countries workshop in January 2010

Conducting the disclosure survey with stakeholders working together

The planned stakeholder mapping and communication audits to take place in July 2010 through the IDS

MeTA Jordan stakeholders have identifies the skills neded to help them communicate with representatives of institutional partners who may come from very different positions, planned between July and Sep. 2010

21/04/23 8


Overall challenges in multi-stakeholder process

A new concept and idea, it needs more time for people to accept and understand

Lack of experience of multi-stakeholder process and the need for different communication skills for members

Inter-personal /inter-institutional communication skills for MeTA Council Members was a challenge, (active listening etc training is needed)

There are currently issues related to Council members listening to each other and putting their point across in a non- confrontational way

People are not all used to operating in a forum where people represent organizations with such different positions and they need support on consensus building

21/04/23 9


Major achievements and successes for MeTA in Jordan (1)

The Government is highly supportive of the MeTA process it supported and hosted MeTA at the HHC, a governmental institution, this gave the whole process an official identity and led to have the diverse public sector more engaged

MeTA was launched in Jordan as a high profile national event in May 09

The highly committed MeTA Council Members started realizing the concept of transparency, they agreed on a national workplan based on the NDP, they agreed to publish all outcomes on Jordan MeTA web site, participated in the data disclosure survey and issued the first MeTA newsletter on April 2010

Jordan had hosted a session at the WHA on transparency and good governance May 09

21/04/23 10



The MeTA process has opened channels of communication between different stakeholders and between different countries. Common understanding of each of the other stakeholder perspectives was identified, the fact that there are common priorities and one objective between stakeholders became more clear

MeTA council private sector representative attended the private sector meeting in London June 09

Pharmaceutical Baseline Assessment Survey-Level II and a WHO/HAI surveys took place

Supply Chain Mapping assessment took place in March 09

A Successful National Forum Nov 09

21/04/23 11



In terms of CSO building capacity area:

The CSO committee has drafted a CSO workplan where it is derived form the three major priorities in the overall national MeTA workplan in Jordan, “Build capacity of (CSOs) to monitor and increase accountability of all stakeholders with respect to the prices, availability, selection and quality of medicines in the public and private sectors

A nucleus of a CSO coalition has started to form and a MoU was signed with the Int. MeTA Secretariat in November 2009 and a specific CSO workplan was approved accordingly the voice of patient is now becoming heard by the Government policy makers

The very first activity was conducted to map and identify CSOs to assess their ability and willingness to work together and to engage them with the MeTA council, this activity has set the baseline work for the CSOs in Jordan

21/04/23 12



In terms of CSO building capacity area:

Workshop on building capacity of CSOs in order to strengthen their ability to monitor and increase accountability of all stakeholders regarding medicines prices, availability, selection and quality of medicines

CSOs have Participated in the Harvard Flagship course and have participated in the country exchange visit to the Philippines

Conduct a training on advocacy and communications in improving access to essential medicinesThe CSO level of engagement with the MeTA process is moving forward gradually

At the start of the process there was limited activities and meeting but since November they become more engaged

21/04/23 MeTA 13



In terms of evidence based medicine:

Reviewed TORs and SOPs of various (therapeutic area-related) committees involved in selection of drugs to be included in Rational Drug List (RDL), reviewed criteria for adding and deleting drugs to and from the RDL, and finally reviewed classification of drugs (Restricted, Un-Restricted, Authorized and Un- Authorized) in RDL

Introduce the pharmaco- economics concept and its importance for RDL addition and deletion to the local industry and generic importers

A series of training sessions on pharmaco-economics to PTC

21/04/23 14



In terms of RDU:

NICE has Pilot the development of an evidence-based care pathway, first step was (STG Gap Analysis in the public sector and second step was developing essential Hypertension STG) for all public primary health care facilities

Conducted a Promotional for Rational Drug Use workshop

21/04/23 15


Overall Challenges (1)

At Pharmaceutical level:

Poor forecasting and estimation of medicines needs which led to low availability of medicines in public sector

High Health expenditure 9.05% of GDP where 34% out of it is spent on medicines with 2/3 expenditure is out of pocket and all this is seen as our fault and Irrational Use of Medicines

Willingness of the private sector to share information, such as information related to prices, promotional activities and quality

High pharmaceutical promotion / hard to control even some patient group's budgets are partially supported by pharmaceutical companies

No base line data to measure outcomes

21/04/23 16


Overall challenges (2)

At the MeTA Level:

Short period, the two year MeTA pilot is not enough to present and measure the impact on the availability and RDU,, as much as we worked and contributed as a sector the outcome will be noticed through years to come

We started the MeTA process with no base line data to rely on, the base line data to be collected started after the MeTA process commenced

Changes in MeTA Council representatives positions/agendas can hinder their participation in medicines policy changes and creates a gap between Council members

Private sector is poorly represented in the MeTA Council

21/04/23 17


Overall challenges (3)

MeTA has acted as a coordinating body for the pharmaceutical sector, also the MeTA process has opened channels of communication between different stakeholders and between different countries

The international and the national MeTA Secretariat coordination role is integral for the MeTA process to move forward

The Consultants Technical Advisory role is of a high value for the MeTA process and in improving quality of implementation of the national workplan

The multi-stakeholders ( public, private and CSOs) process in very hard, it takes time to have the stakeholders understand each other's perspectives and identify that there were in fact common priorities and one objective to work on together

21/04/23 18


Overall Challenges (4)

At the MeTA Level:

CSOs are still not represented in drug related committees like the Pricing Committee or Higher Drug Committee

Difficulty in attracting new CSO groups to join the MeTA CSO coalition and there is an absence of coordination or sharing of expertise and experiences among the various CSOs

Limited participation of CSO representatives in MeTA Baseline Data Disclosure Survey and no coordination for the CSOs work

Poor role of the CSOs in the decision making process with limited role in patient counseling

21/04/23 19


Lessons Learned (1)

To continue exploring national opportunities for pursuing MeTA post-pilot in Jordan

Looking for sustainability when MeTA ends in the country, we need to keep searching for other fund and contact other international partners like EU

Opening channels with media to engage external stakeholders with the MeTA process and raise public awareness

To recommend activities and present a prioritised workplan to the International MeTA Secretariat for discussion as soon

MeTA has acted as a coordinating body for people working in the pharmaceutical sector

21/04/23 20


Lessons Learned (2)

CSO engagement with the MeTA process complements the overall picture and highlights patients’ need. Capacity for CSOs to engage more effectively needs to be built

A budget for a CSO coordinator should have been listed in the CSO workplan and there should be an organized structure for the CSO coalition

To engage parliament in the MeTA council process

The stakeholders started to understand each others perspectives

21/04/23 21


Lessons Learned (3)

We have learned the Importance of Data Disclosure, many outputs we were keen to participate in towards disclosure, we agreed to publish all outcomes on Jordan MeTA Web site and learned that we should involve media more

The MeTA process has opened channels of communication between different stakeholders and between different countries

MeTA has acted as a coordinating body for the pharmaceutical sector players and stakeholders

The Data Disclosure survey was a useful exercise that improved communication and sharing/disclosing of information- a core MeTA principle

21/04/23 22


Thank you for Listening

Dr Taher Abu El Samen Email: [email protected]

Mobile number: +962 79 726 7444

Website: www.meta.jo

mailto:[email protected]

http://www.meta.jo/


Public Sector

Presenter NameJob Title


Overview of Public Health Sector in Jordan

21/04/23 MeTA 25

Jordan is characterized by a diverse and fragmented public sector. It consists of: MOH, Royal Medical Services, Jordan University Hospital, King Abdullah the Second University Hospital, King Husain Cancer Center and Prince Hamzeh Hospital

The public sector covers about 72% of the population Pharmaceutical expenditure as a percent of total health expenditure is 34.0%,

where public accounts for 11.3%

Public pharmaceutical expenditure as a percentage of total pharmaceutical expenditure accounts for 33.3%.

Pharmaceutical expenditure is growing at 17% per annum compared to GDP growth of 3.3%

The public sector is represented at the Jordan MeTA Council by 9 members out of 18

Source: Jordan National Health Accounts (NHA) 2007


Comparison of Jordan Public Expenditure on Medicines with other Countries

26


Level of Public Sector Engagement

The Government/ public sector has supported MeTA since the start of MeTA

The public sector actively participates in all MeTA activities at the level of the Council, subcommittees and established task forces that work on activities in our national workplan

MeTA Council representatives of the Public sector have acted as facilitators for the Baseline Pharmaceutical Assessment Household and Health Facility survey level II, as well as the Pharmaceutical Sector Scan

The Public Sector is fully committed and are the main drivers for the MeTA process in Jordan

21/04/23 MeTA 27


Level of Public Sector Engagement cont.

MeTA is hosted at one of the public health sector institutions/ the High Health Council (HHC)

The elected MeTA Chair is the Secretary General of the HHC

Representatives from public sector were nominated to participate in the household and health facility survey level II technical committee.

Representative pharmacists from public sector institutions participated in facility survey data collection

Most of public sector representative at the MeTA Council actively participated in the baseline data disclosure survey

21/04/23 MeTA 28


Summary Analysis at start of MeTA

The needs and issues in the public sector at the start of MeTA focused on three main areas:

Improving Availability in the public sector through adapting and using transparent evidence based decision making for the Rational Drug List (RDL)

Promoting Rational Drug Use through encouraging best practice and developing STGs

The need for reliable Data to be used in forecasting etc. especially with the lack of Health IT within the public sector


Major Milestones

Developed national Standard Treatment Guidelines (STGs) for essential hypertension for all public primary health care facilities

(Expected Output: implementation of pilot STG after discussing implementation strategy with MoH)

Reviewed TORs and SOPs of various (therapeutic area-related) committees involved in selection of drugs to be included in Rational Drug List (RDL)

(Expected Output: adoption of revised criteria for SOPs and Conflict of Interest declarations and increased accountability)

Reviewed criteria for adding and deleting drugs to and from RDL(Expected Output: adoption of revised criteria and increased

transparency in medicines selection processes)

Reviewed classification of drugs (restricted, unrestricted, authorized and unauthorized) in RDL

(Expected Output: adoption of revised classifications using transparent evidence based medicine criteria to inform decisions)

21/04/23 30


Major Milestones cont.

For reliable data on medicines availability and use they advised to have the Pharmaceutical Baseline Assessment Survey-Level II and a WHO/HAI surveys to take place and contributed data to them

Supported and contributed to a Supply Chain Mapping Assessment

Promoted a Rational Drug Use workshop amongst public sector health workers

Advised that a series of training sessions on pharmaco-economics take place for health professionals -to date two training sessions have already taken place

Promote good practice and work on the development of conflict of interest (COI) declaration and management system for all committees to improve accountability

21/04/23 31


Successes

The Government is highly supportive for the MeTA initiative in Jordan as mentioned earlier

The public sector is committed to MeTA and they believe in the MeTA main objective and the five core principles

The Government has supported MeTA and hosted the initiative at one of the governmental institutions -the HHC. This gave the whole process an official identity and led to the fragmented public sector working together towards improving availability through adapting/using evidence based decision making for the Rational Drug List (RDL) and promoting RDU through encouraging best practice

21/04/23 32


Challenges

At the level of the Pharmaceutical Sector:

Poor forecasting and estimation of medicines needs which leads to low availability of medicines in public sector

High Health expenditure 9.05% of GDP where 34% out of it is spent on medicines with 2/3 expenditure is out of pocket

Direct local purchases by institutions (prices of the private sector) instead of sticking to procuring jointly through JPD

Irrational Use of Medicines and absence of national STGs in different disease areas

Weak role and capacity of pharmaco- vigilance system

Lack of private sector transparency

21/04/23 33


Challenges cont.

General Challenges:

The two year period for MeTA pilot is too short and not long enough to measure outcomes and impact on the availability of medicines in the public sector and on Rational Drug Use

Changes in MeTA Council representatives positions/agendas can hinder their participation in effecting medicines policy changes and creates a gap between Council members

21/04/23 34


Lessons Learned

1. The main lesson learned is the importance of partnership AND the multi-stakeholder process:

That public sector can be more effective in dealing with issues within the medicine supply chain in terms of availability, distribution, RDU when working with the private sector and civil society organizations (CSO), since the private sector secures the country with medicines and the CSO speak on behalf of patients’ and consumers’ and their needs

The MeTA process has opened channels of communication between different stakeholders and between different countries

MeTA has acted as a coordinating and facilitating body for the pharmaceutical sector players and stakeholders

21/04/23 35


Lessons Learned cont.

2. We have learned the Importance of Data and Data Disclosure

Participated fully in the Pharmaceutical Sector Data Disclosure Survey

Contributed fully in the Pharmaceutical Baseline Assessment Survey-Level II: Facility and household and included the Pricing Survey within the baseline assessment facility survey

Participated in the Pharmaceutical Sector Scan Survey

Agreed to publish all outputs and data on Jordan MeTA Web site and learned that the media should be more involved

Identified gaps and formulated recommendations for the Jordan pharmaceutical sector (based on existing pharmaceutical reform sector studies (WB 2004) and publish on the Jordan MeTA Web site

21/04/23 36


Thank you

Name of presenter:

Job Title: Email:

Mobile number: +962

Website: www.meta.jo

http://www.meta.jo/


Private Sector

Dr Ibrahim Al Abbadi

Scientific Research Documentation Office Director

The University of Jordan


Overview of Private Health Sector in Jordan

21/04/23 MeTA 39

60 private hospitals and many specialized private clinics

16 High quality local pharmaceutical manufacturing (branded generics)

Value of Jordan pharmaceutical market (2008) is 350m USD

80% (in value) corresponds to imported medicines

84 medicines’ local agents and around 160 subagents

1829 registered pharmacies

Reference: Jordan National Health Accounts (NHA) 2007 and Jordan Supply Chain Mapping report (2009)


Overview of Private Health Sector in Jordan Cont.

Chain pharmacies started operating in Jordan since 2001, the biggest is Pharmacy One with 45 branches

Pharmaceutical expenditure as a percent of total health expenditure is 34.0% where the private sector accounts for 22.7%

Distribution of pharmaceutical expenditure as a percentage of total pharmaceutical expenditure where the private accounts for 66.7%

Reference: Jordan National Health Accounts (NHA) 2007 and Jordan Supply Chain Mapping report (2009)21/04/23 40


Jordanian Pharmaceutical Exports million US $

21/04/23 MeTA 41

The Target is 1 billion $ in 2011

Source: Jordan Association of Pharmaceutical Manufactures(2010)



The main issues for the private sector at the start of MeTA were:

To get engaged more in the strategic planning process for the pharmaceutical sector in our country, and to get engaged more with the public sector and to share data and information on availability and patients needs


Major milestones

The private sector represented by the local industry association as one of the MeTA council members

The Medical and Pharmacy associations are represented in the MeTA council

Participated in most of MeTA activities on the level of the council membership , the level of subcommittees and on the level of established task forces that are working on activities listed on our national workplan

The MeTA council representatives of the private sector acted as facilitators for the baseline pharmaceutical surveys

Encouraged the private sector mapping report to be conducted

To conduct a workshop to promote ethical promotion guidelines

21/04/23 43


Major milestones Cont.

Introduce the pharmaco-economics concept and its importance for RDL addition and deletion to the local industry and generic importers

An introductory meeting about MeTA and its concept to the medical associations and professional associations

Contributed in reviewing the criteria for adding and deleting medicines into the RDL , TORs and SOPs for the RDL committees, revised the classification criteria of drugs (Restricted, Un-Restricted & Authority required) listed in the RDL

MeTA Council Private sector representative (local pharmaceutical industry), attended Private Sector meeting in London June 2009

Agreed with the MeTA Council to publish all outcomes on Jordan MeTA Web site

21/04/23 44


Successes

The private sector is represented by the local pharmaceutical industry, Jordan Pharmacy Association and Jordan Medical Association

The private sector participate in regular meetings and in most activities

The private sector represented by the local industry will participate in a study about the FTA impact on access to medicine in Jordan

Were involved in reviewing criteria for adding and deleting drugs to and from the RDL and the TORs and SOPs of various (therapeutic area-related) committees involved in selection of drugs to be included in Rational Drug List (RDL) and the classification of drugs (Restricted, Un-Restricted, Authorized and Un- Authorized) in RDL

21/04/23 45


Challenges

At Pharmaceutical level:

Poor forecasting and estimation of medicines needs which leads to low availability of medicines in public sector where this will reflect on us as a private sector

High Health expenditure 9.05% of GDP where 34% out of it is spent on medicines with 2/3 expenditure is out of pocket

High prices of some essential medicines since the private sector is securing the country with medicines

21/04/23 46


Challenges Cont.

Private sector is not fully represented in the MeTA Council

Private sector low level of disclosing data and low willingness to share information, such as information related to prices, promotional activities and quality

Few patients associations budgets are partially supported by pharmaceutical companies

High pharmaceutical promotion / hard to control

21/04/23 MeTA 47


Challenges Cont.

Short period, the two year MeTA pilot is not enough to present and measure the impact on medicines availability and RDU, as much as we worked and contributed as a sector the outcome will be noticed through years to come

In order to present as a sector that we contributed to the main issues identified we needed more time to have this contribution measured by data to be presented to the whole public

Lack of adherence to ethical promotion guidelines

21/04/23 48


Lessons Learned

The need to engage our private sector more in the MeTA process

MeTA has acted as a coordinating body for the pharmaceutical sector players and stakeholders

The MeTA process has opened channels of communication between different stakeholders and different countries

CSO as one of the stakeholder engagement with the MeTA process complements the overall picture and highlights patients’ need

Reach a common understanding on concepts of pharmaco-economics , transparency, evidence-based medicine (EBM) and accountability

21/04/23 49


Lessons Learned Cont.

To engage parliament in the MeTA council process and to involve the media more

We started to understand each of the other stakeholder perspectives and identified that there were in fact common priorities and one objective between us to work on together

The Data Disclosure survey was a useful exercise that improved communication and sharing/disclosing of information which is a core MeTA principle

We have learned the importance of data disclosure and sharing information

21/04/23 MeTA 50


Thank you

Ibrahim Alabbadi

PharmacoEconomist Email: [email protected]

Mobile number: +962-777160810

Skype:

Website: www.ju.edu.jo


Civil Society

Dr Abdel Fattah Al KilaniMeTA Council Member


CSO Sector overview

A total of 240 societies are registered officially in the ministry of social development, yet not all are active neither represents patient groups

The history in working with the Civil Society Organizations in Jordan started in March 2008 when (HAI) facilitated a meeting/workshop for the CSO with the objective of bringing civil society groups together to take a decision as a group to form an independent alliance that will work effectively to enhance its role in policy planning and presenting the WHO/HAI survey results to them

21/04/23 MeTA 53



Limited CSO role in influencing healthcare strategies and policies in Jordan

Limited effectiveness and authority in solving patients’ problems regarding availability and affordability of medicines

Major limitation on the CSO’s fundraising ability due to restriction by the Ministry of Social Development on the number of fundraising events (only two annually)

There is an absence of coordination or sharing of expertise and experiences among the various CSOs

21/04/23 54


Summary Analysis at start of MeTA Cont.

At the early stage of MeTA, the MeTA/ CSO committee has identified the following areas to include in the CSO workplan:

Priority Area 1: Engaging Civil Society Organizations (CSOs) to work together on promoting Transparency in the Medicines Supply Chain and improve Access to Medicines

Priority Area 2: To continue to build capacity among CSOs to analyze data and explore and recommend policy options around medicines availability and affordability, promotion and prescribing practices, RDU and the use of generics

Priority Area 3: Communication and Coordination

21/04/23 55


Major milestones

The very first activity was conducted to map and identify CSOs to assess their ability and willingness to work together and to engage them with the MeTA council, this activity has set the baseline work for the CSOs in Jordan

Workshop on building capacity of CSOs in order to strengthen their ability to monitor and increase accountability of all stakeholders regarding medicines prices, availability, selection

and quality of medicines in the public and private sectors . The main objective of the workshop was to introduce CSOs to medicines regulations and health polices

Participate in the Harvard Flagship course

Participate in the country exchange visit to the Philippines

Conduct a training on advocacy and communications in improving access to essential medicines

21/04/23 56


Success

The MeTA Council has identified Building capacity in pharmaceutical policies for CSOs as one of its three main areas in the country workplan

The CSO committee has drafted a CSO workplan according to the three major priorities in the overall national MeTA workplan in Jordan, “Build capacity of (CSOs) to monitor and increase accountability of all stakeholders concerning the prices, availability, selection and quality of medicines in the public and private sectors

The specific CSO workplan was approved and a MOU has been signed

CSOs are engaged in the MeTA initiatives

A nucleus of CSO coalition started to form

21/04/23 MeTA 57


Success Cont.

The CSO level of engagement with the MeTA process is moving forward gradually

At the start of the process there was limited activities and meetings but since November 09 they became more engaged

The CSO representative and patient groups actively participated in all MeTA Jordan activities ( MeTA launch, MeTA forum, many workshops)

The voice of patient is becoming heard from policy makers in the public sector/ example MS patient society

Patient group representatives has 2 seats in the MeTA council

A workshop on advocacy and communication was organized for CSOs with emphasis on team building activity, communication skills, persuasion & negotiation skills, advocacy, how to form a Coalition and engagement with the Media

21/04/23 58


Challenges

Poor role of the CSOs in the decision making process

Few of the patient groups societies budget is partially supported by pharmaceutical companies

CSOs are still not represented in medicines related committees such as : the pricing committee, higher drug committee / JFDA

Limited CSOs role in improving patient counseling

Encouraging new patient groups societies to join the coalition is a challenge

Shortages of medicines availability in public health and high prices of medicine in the private sector

21/04/23 MeTA 59


Challenges Cont.

Limited participation of CSO representatives in Data disclosure survey tool

MOU has taken some time to be approved and signed, accordingly funds were not available for CSO until a later stage

CSOs need a coordinator to follow up on the activities listed in their work plan

Reach a common understanding on the role of the patients focusing on the regulations ,distribution of medicines and rational drug use

21/04/23 60


Lessons Learned

A budget for a CSO coordinator should have been listed in the CSO workplan

CSO engagement with the MeTA process complements the overall picture and highlights patients’ need

Capacity for CSOs to engage more effectively needs to be built

To engage parliament in the MeTA council process

There should be an organized structure for the CSO coalition and the CSO already started working towards forming an organized way on, also formed a three committees on their meeting on the 22 June 2010

21/04/23 61


Lessons Learned Cont.

More participation of CSO representatives in Data disclosure survey tool should have been considered

To involve media more

The stakeholders started to understand each others perspectives CSOs realized that this should have been happened earlier

The CSO engagement with the process complement the overall picture and uncovers the patients’ needs

21/04/23 62

Patient Groups NGOs MediaDiabetes Association

Jordan cancer society

Jordan ass. For hemophilia & Thalasemia

Environmental Protection Society

Jordan Association for Consumer Protection

AL GHAD newspaper- Jordan

cerebral palsy foundation

Kidney patients friends society

Jordan ass. For diabetic and cancer pt.

Jordanian society for tonsumer protection

Jordan medical association

IBN-CINA FOR CELEBRAL palsy

Jordan Rose of Hope Society for arthritis pt.

Jordanian psychiatric rehabilitation society

Jordan pharmacist association

Garden and Home Association

liver patients friends society

Jordanian friends of behcet's disease pt. society

Jordan society for phenyl-keton urea

Jordan cultural ass. For development of law and legal capacities

multiple sclerosis society

The Jordanian friends of cystic fibrosis association

Examples of Interested Civil Society Organizations


Thank you

Dr Abdel Fattah Al Kilani

Consumer Protection Organization Representative Email [email protected]

Mobile number +962 799958059

Website www.meta.jo

Medicines Transparency Alliance13/09/2015 1 MeTA Jordan Country Overview Public Sector Private...

Documents

Transcript of Medicines Transparency Alliance13/09/2015 1 MeTA Jordan Country Overview Public Sector Private...